The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C.sub.1-C.sub.4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C.sub.1-C.sub.4) or an aminoalkyl 10 (C.sub.1-C.sub.4) methacrylamide, and reacting the resulting aminoalkyl (C.sub.1-C.sub.4) maleimide or the aminoalkyl (C.sub.1-C.sub.4) methacrylamide to a cysteine or other sulfur group. Targeting moieties are bonded to the polymer, for example, by reacting a carboxylate moiety on a polymer with a N-hydroxysuccinimide or a carbodiimide, and reacting the intermediate formed with a lysine or arginine group on a targeting peptide to produce polymer-amide-peptide. Other 15 aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

A method of killing AGE-modified cells comprises applying ultrasound to a subject and administering to the subject a composition comprising an anti-AGE antibody. The applying of ultrasound may occur before or after the administering of the anti-AGE antibody. The AGE-modified cells may be in a restricted site.

A polypeptide modified complex in the pharmaceutical field that can specifically adsorb apolipoproteins in plasma and can mediate a drug across the blood-brain barrier, a target delivery system, and use thereof in preparation of a formulation for diagnosing and treating brain tumors and other brain diseases. The polypeptide fragment (SP) of the amyloid β (relating to one type) is modified shown that the modified delivery system increases uptake the of the amyloid β by vascular endothelial cells after the modified delivery system forms a protein crown with plasma proteins. The modified liposome delivery system delivers a drug to the lesion site more effectively, significantly improving the therapeutic effect of the drug. After the SP adsorbs plasma proteins, a drug may be mediated across the blood-brain barrier and/or targeted to tumor neovascular and tumor cells, and the modified drug and delivery system thereof obtain a better therapeutic effect when treating brain tumors and other diseases in the brain.

Systems, devices, and methods are provided that are useful in generating a fluid suspension of nanoplasmoid bubbles. Such systems utilize a nanobubble/nanoplasmoid generator in conjunction with mechanisms for applying energy to the fluid in the form of electrolytic events, pressure waves, electrical fields, and/or magnetic fields. The nanobubble/nanoplasmoid generator is of modular construction that is readily adaptable to a wide variety of applications. Various applications of nanoplasmoid bubble suspensions so produced are described.

The present disclosure provides a for peptoid compounds that bind selective to cancer stem cells (CSCs), particularly those associated with breast cancer. Conjugates of the peptoids to detactable labels and therapeutic agent are contemplated as are methods of diagnosing and treating breast cancer.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

A macroporous polymeric hydrogel microsphere that contains poly(ethylene glycol), chitosan, and water. The hydrogel microsphere, having a diameter of 50-250 μm and a mesh size of 5-100 nm, is capable of transporting biomolecules conjugated to it. Also disclosed is a method of fabricating the microsphere based on a micromolding technique utilizing surface tension-induced droplet formation followed by photo-induced polymerization.

Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a suspension of preformed lipid nanoparticles and mRNA.

Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of β-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient.